Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
Arq. bras. endocrinol. metab ; 54(2): 239-243, Mar. 2010. graf, tab
Article in English | LILACS | ID: lil-546269

ABSTRACT

OBJECTIVE: To evaluate the bioavailability of vitamin D in capsules as compared with oily drops in nuns living in a closed community with very low sun exposure. METHODS: A randomized, 2 x 2 crossover, open clinical trial was conducted, with 18 nuns aged between 20 and 75 years. Samples were collected in the fasting state and at 4, 8, 12 and 24 hours following the administration of capsules and oily drops (both containing vitamin D3 66,000 UI plus vitamin A 13,200 UI) to determine serum 25 hydroxivitamin D concentrations (25OHD), at baseline and 90 days after. The evaluation was based on the maximum concentration (Cmax) and area under the curve (AUC0-24). RESULTS: The capsule formulation presented Cmax and AUC0-24, 5.78 percent and 0.76 percent, respectively, greater than the oily drops formulation. CONCLUSION: Both formulations were within the limits for a bioequivalence study, namely C-90 percent for Cmax and AUC0-24, and the drugs were considered bioequivalent.


OBJETIVO: Avaliar a biodisponibilidade da vitamina D3 em cápsulas, comparando com gotas oleosas, em religiosas que vivem em comunidade fechada com baixa exposição solar. MÉTODOS: Ensaio clínico aberto, aleatório e cruzado 2 x 2, com 18 religiosas (20-75 anos de idade). As amostras foram coletadas em jejum e 4, 8, 12 e 24 horas após a administração de cápsulas e de gotas oleosas (ambos contendo 66.000 UI de vitamina D3 e 13.200 UI de vitamina A) para dosagem da 25 hidroxivitamina D (25OHD), em data base e 90 dias após. A avaliação baseou-se nos resultados da concentração máxima (Cmáx) da 25OHD e da área sob a curva (ASC0-24). RESULTADOS: A análise descritiva desses parâmetros demonstrou que a cápsula apresentou Cmáx e ASC0-24 de 5,78 por cento e 0,76 por cento a mais que as gotas oleosas, respectivamente. CONCLUSÃO: Ambas as formulações encontravam-se dentro dos limites de aceitação em estudo de bioequivalência IC-90 por cento para Cmáx e ASC (0-24), daí as drogas serem consideradas bioequivalentes.


Subject(s)
Adult , Aged , Female , Humans , Middle Aged , Young Adult , Cholecalciferol/administration & dosage , Cholecalciferol/pharmacokinetics , Vitamin D Deficiency , Area Under Curve , Biological Availability , Capsules , Cross-Over Studies , Cholecalciferol/chemistry , Therapeutic Equivalency , Time Factors , Vitamin D Deficiency/blood , Vitamin D Deficiency/prevention & control , Vitamin D/analogs & derivatives , Vitamin D/blood
SELECTION OF CITATIONS
SEARCH DETAIL